Clearpoint Neuro Inc Cash Flow Conversion Efficiency
Clearpoint Neuro Inc cash flow conversion efficiency. Based on the latest financial reports, Clearpoint Neuro Inc (CLPT) has a cash flow conversion efficiency ratio of -0.651x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.01 Million) by net assets ($10.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Clearpoint Neuro Inc (2011–2025)
Cash flow conversion efficiency of Clearpoint Neuro Inc from 2011 to 2025. This chart illustrates how Clearpoint Neuro Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Clearpoint Neuro Inc for real-time trading data and today's change.
Clearpoint Neuro Inc Cash Flow Conversion Ratio Explained
Clearpoint Neuro Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Clearpoint Neuro Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Clearpoint Neuro Inc ranked by their cash flow conversion efficiency. Also see CLPT stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hubei Mailyard Share Co Ltd
SHG:600107
|
0.010x |
|
Beijing Hanjian Heshan Pipeline Co Ltd
SHG:603616
|
-0.114x |
|
Global Tax Free Co. Ltd
KQ:204620
|
0.123x |
|
HomeStreet Inc
NASDAQ:HMST
|
-0.024x |
|
GNA Axles Limited
NSE:GNA
|
0.151x |
|
Pure Cycle Corporation
NASDAQ:PCYO
|
-0.028x |
|
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
|
-0.002x |
|
Shanghai Aiyingshi Co Ltd
SHG:603214
|
0.057x |
Annual Cash Flow Conversion Efficiency for Clearpoint Neuro Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Clearpoint Neuro Inc from 2011 to 2025. Review Clearpoint Neuro Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $28.02 Million | $-23.93 Million | -0.854x | -142.22% |
| 2024-12-31 | $25.39 Million | $-8.95 Million | -0.353x | +45.60% |
| 2023-12-31 | $21.17 Million | $-13.72 Million | -0.648x | -47.85% |
| 2022-12-31 | $36.89 Million | $-16.17 Million | -0.438x | -68.41% |
| 2021-12-31 | $48.79 Million | $-12.70 Million | -0.260x | +92.08% |
| 2020-12-31 | $2.38 Million | $-7.81 Million | -3.285x | -428.66% |
| 2019-12-31 | $4.59 Million | $-2.85 Million | -0.621x | +79.72% |
| 2018-12-31 | $1.51 Million | $-4.63 Million | -3.065x | -198.08% |
| 2017-12-31 | $5.83 Million | $-5.99 Million | -1.028x | -113.36% |
| 2016-12-31 | $-756.07K | $-5.82 Million | 7.698x | +76.55% |
| 2015-12-31 | $-1.98 Million | $-8.64 Million | 4.360x | -93.97% |
| 2014-12-31 | $-100.33K | $-7.25 Million | 72.265x | +6249.42% |
| 2013-12-31 | $-6.83 Million | $-7.78 Million | 1.138x | -12.16% |
| 2012-12-31 | $-5.74 Million | $-7.43 Million | 1.296x | +353.61% |
| 2011-12-31 | $-21.84 Million | $-6.24 Million | 0.286x | -- |
About Clearpoint Neuro Inc
ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which … Read more